完美醫療(01830.HK)年度收入減少19.1%至11.28億港元
格隆匯6月27日丨完美醫療(01830.HK)公吿,截至2025年3月31日止年度全年業績,集團全年收入減少19.1%至11.28億港元。股東應占溢利減少34.5%至2.07億港元。建議末期股息為每股5.3港仙,年度股息為每股16.6港仙。年度派息比率為100.6%。
受經濟疲弱及消費意欲低迷影響,香港市民傾向外遊消費及中國內地市場價格競爭激烈,影響集團年度的業績表現。集團加大力度提升各項應對措施,集中推出高性價比韓國醫美服務,並加強會員忠誠度計劃以刺激消費和提升銷售。儘管市場環境困難,集團業務展現出韌性,有效維持18.3%超高淨利潤率。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.